Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CRVS

Corvus Pharmaceuticals

CRVS Rare disease Lead: Phase 3 ★ Read the deep dive → 2 Biotech Distilled articles ↓ 25 filings & releases ↓ Cash $15.0M (Sep 30, 2026) ↓ 2 verdicts ↓ 1 timing quote ↓
DermatologyOncologyRespiratory ProteinSmall Molecule

Market cap $889M 84.4M shares (10-Q, Nov 5, 2026) × $10.54 close Nov 6, 2026

Most recent annual filing: 2026-03-12

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Soquelitinib PTCL Ph3 interimLate 2026Soquelitinib PTCL Ph3 interim, Late 2026, notable
  2. Soquelitinib AD Ph3 interimMar 2027Soquelitinib AD Ph3 interim, Mar 2027, notable
  3. Soquelitinib Atopic Dermatitis Ph2 topline3Q 2027Soquelitinib Atopic Dermatitis Ph2 topline, 3Q 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Capital (as filed)

Cash
$15.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$188M Sep 30, 2026
Operating cash flow
−$12.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$203M cash, runway Q2 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Corvus Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-19 Buy core Corvus Pharmaceuticals (CRVS) - Scientific Deep Dive for Soquelitinib and Pipeline Products Soquelitinib's pristine ITK-inhibition mechanism, clean Phase 1 safety/efficacy data, and a fully-funded balance sheet (runway into Q2 2028) make CRVS a high-conviction catalyst play ahead of the pivotal 1H 2027 Phase 2 AD readout.
  2. 2026-11-06 Buy core UPDATE: Corvus Pharmaceuticals (CRVS) - The Clock Slides Into 2027 BUY maintained despite two Late 2026 catalysts slipping to 2027 and ciforadenant being shelved, as the balance sheet remains intact, safety record is clean, and the core soquelitinib thesis is unchanged; stock trading below half the offering price may justify patient accumulation.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)